| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,600 | ₹4 0% | 2500% |
| - | - | 4,700 | ₹2.5 -76.95% | 1,250-37.5% |
| - | - | 4,800 | ₹3.95 -26.85% | 3750% |
| - | - | 4,900 | ₹5 -58.5% | 2,2500% |
| 5000% | ₹461.45 0% | 5,000 | ₹6 -38.14% | 8,000-5.88% |
| - | - | 5,050 | ₹10 0% | 1,1250% |
| - | - | 5,100 | ₹8.05 -39.47% | 62525% |
| 1250% | ₹430 0% | 5,200 | ₹14.85 -29.62% | 29,25095% |
| 37550% | ₹460.6 45.66% | 5,250 | ₹21.35 -26.12% | 5,25035.48% |
| 3750% | ₹312.75 0% | 5,300 | ₹29.9 -17.28% | 4,62554.16% |
| 5000% | ₹284.3 0% | 5,350 | ₹58 0% | 3,0000% |
| 2,3750% | ₹297 0% | 5,400 | ₹50.15 -6.95% | 18,75018.11% |
| 2,6255% | ₹298.3 16.29% | 5,450 | ₹58 -16.96% | 12,00074.54% |
| 15,125-14.78% | ₹264.45 13.2% | 5,500 | ₹73.8 -14.33% | 9,500-1.29% |
| 7,375-1.66% | ₹220.5 7.9% | 5,550 | ₹94.1 -11.01% | 32,625-1.13% |
| 16,625-47.01% | ₹197.75 13.42% | 5,600 | ₹110 -12.1% | 8,500-69.77% |
| 6,00050% | ₹166 11.93% | 5,650 | - | - |
| 42,500407.46% | ₹138.9 10.1% | 5,700 | ₹158.7 -10.03% | 28,3752422.22% |
| 3,5000% | ₹70 0% | 5,750 | ₹271.95 0% | 2500% |
| 8,87569.04% | ₹91.05 2.64% | 5,800 | ₹216.05 -9.97% | 1,750133.33% |
| 11,50016.45% | ₹67.15 6.67% | 5,900 | ₹522.75 0% | 1250% |
| 2,2500% | ₹58 0% | 5,950 | - | - |
| 17,25053.33% | ₹45.05 1.57% | 6,000 | ₹469.6 0% | 2500% |
| 1,12580% | ₹40 8.25% | 6,050 | - | - |
| 7,75012.72% | ₹32.45 7.09% | 6,100 | - | - |
| 7,00080.64% | ₹19.65 -6.65% | 6,200 | - | - |
| 2500% | ₹8 0% | 6,300 | - | - |
| 3,3758% | ₹9.1 -19.11% | 6,400 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
